🎗️ Melanoma — 2026-W38

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Systematic review and meta-analysis of phase 3 trials examining how patient sex and timing (neoadjuvant vs adjuvant) affect outcomes with curative-intent immune checkpoint inhibitors across solid tumors, published in JAMA Network Open. Findings could inform how oncologists interpret and sequence perioperative immunotherapy across tumor types by patient sex.

Proof-of-concept translational study in JCO Precision Oncology combining single-cell Raman spectroscopy with machine learning to predict resistance to targeted and immunotherapy agents in melanoma cell lines and patient samples. Could inform future biomarker-driven treatment selection pending larger validation.

Narrative review of tumor-infiltrating lymphocyte therapy for advanced/refractory melanoma, published in Curr Treat Options Oncol. Summarizes current TIL products, manufacturing, and emerging combination strategies relevant to clinicians considering cellular therapy options.

Descriptive analysis of FDA (neo)adjuvant drug approvals for solid tumors (2010-2023), published in JNCI, spanning melanoma, breast, and lung cancer trials. Highlights inconsistencies in trial design, endpoint reporting, and quality-of-life data that inform how oncologists interpret the evidence behind approved (neo)adjuvant regimens.